Attached files
file | filename |
---|---|
8-K - FORM 8-K - Change Healthcare Holdings, Inc. | d535917d8k.htm |
Exhibit 99.1
FOR IMMEDIATE RELEASE
Emdeon Reports First Quarter 2013 Results
| Revenue of $305.7 million for First Quarter 2013 |
| Adjusted EBITDA of $76.0 million for First Quarter 2013 |
NASHVILLE, Tenn. (May 9, 2013) Emdeon Inc., a leading provider of healthcare revenue and payment cycle management and clinical information exchange solutions, today announced financial results for the first quarter ended March 31, 2013 as summarized below:
(In millions) | 1Q 2013 | 1Q 2012 | % Change | |||||||||
Revenue |
$ | 305.7 | $ | 286.0 | 6.9 | % | ||||||
Net Income (Loss) |
$ | (13.5 | ) | $ | (17.5 | ) | 23.3 | % | ||||
Non-GAAP Adjusted EBITDA |
$ | 76.0 | $ | 78.4 | -3.1 | % |
Our operating results for the first quarter were solid, and particularly strong in payment distribution services and revenue cycle solutions, said George Lazenby, chief executive officer for Emdeon. We remain pleased with the overall performance of our businesses and continue to invest in new initiatives to support our long-term growth strategies.
First quarter revenue was $305.7 million, an increase of 6.9%, compared to $286.0 for the same period in 2012. Net loss for the first quarter of 2013 was $13.5 million compared to $17.5 million for the same period in 2012. This improvement in net loss compared to the corresponding prior year period was primarily due to the impact of business growth and lower interest expense as a result of the repricing of Emdeons term debt in April 2012.
First quarter 2013 Non-GAAP Adjusted EBITDA decreased 3.1% to $76.0 million, or 24.9% of revenue, from Non-GAAP Adjusted EBITDA of $78.4 million, or 27.4% of revenue, for the comparable period in 2012. This decline in Adjusted EBITDA as compared to the same period in 2012 is primarily due to increased investments related to sales and other growth initiatives and one less business day in the first quarter of 2013.
A reconciliation of Emdeons financial results determined in accordance with U.S. Generally Accepted Accounting Principles (GAAP) to certain non-GAAP financial measures has been provided in the financial statement tables included in this release to supplement its unaudited condensed consolidated financial statements presented on a GAAP basis. An explanation of these non-GAAP measures is also included below under the heading Explanation of Non-GAAP Financial Measures.
About Emdeon
Emdeon is a leading provider of revenue and payment cycle management and clinical information exchange solutions, connecting payers, providers and patients in the U.S. healthcare system. Emdeons offerings integrate and automate key business and administrative functions of its payer and provider customers throughout the patient encounter. Through the use of Emdeons comprehensive suite of solutions, which are designed to easily integrate with existing technology infrastructures, customers are able to improve efficiency, reduce costs, increase cash flow and more efficiently manage the complex revenue and payment cycle and clinical information exchange processes. For more information, visit www.emdeon.com.
Forward-Looking Statements
Statements made in this press release that express Emdeons or managements intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. These statements often include words such as may, will, should, believe, expect, anticipate, intend, plan, estimate or similar expressions. Forward-looking statements may include information concerning Emdeons possible or assumed future results of operations, including descriptions of Emdeons revenues, profitability, outlook and overall business strategy. You should not place undue reliance on these statements because they are subject to numerous uncertainties and factors relating to Emdeons operations and business environment, all of which are difficult to predict and many of which are beyond Emdeons control. Although Emdeon believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect Emdeons actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. Such factors related to Emdeons actual financial results or results of operations include: effects of competition, including competition from entities that are customers for certain of Emdeons solutions; Emdeons ability to maintain relationships with its customers and channel partners; Emdeons ability to effectively cross-sell its solutions to existing customers and to continue to generate revenue and maintain profitability by developing or acquiring and successfully deploying new or updated solutions; pricing pressures on Emdeons solutions; the anticipated benefits from acquisitions not being fully realized or not being realized within the expected time frames; and general economic, business or regulatory conditions affecting the healthcare information technology and services industries; as well as the other risks discussed in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections and elsewhere in Emdeons Annual Report filed on Form 10-K for the year ended December 31, 2012, as well as other reports filed by Emdeon with the Securities and Exchange Commission.
You should keep in mind that any forward-looking statement made by Emdeon herein, or elsewhere, speaks only as of the date on which made. Emdeon expressly disclaims any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in Emdeons expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
# # #
Contacts:
Investor Relations
Bob East
Westwicke Partners
443.213.0502
bob.east@westwicke.com or
Emdeon@westwicke.com
2
Emdeon Inc.
Condensed Consolidated Statements of Operations
(unaudited and amounts in thousands)
Three Months | Three Months | |||||||
Ended March 31, | Ended March 31, | |||||||
2013 | 2012 | |||||||
Revenue |
$ | 305,702 | $ | 286,035 | ||||
Costs and expenses: |
||||||||
Cost of operations (exclusive of depreciation and amortization below) |
189,307 | 173,146 | ||||||
Development and engineering |
7,722 | 9,085 | ||||||
Sales, marketing, general and administrative |
39,111 | 36,127 | ||||||
Depreciation and amortization |
46,815 | 45,156 | ||||||
Accretion |
4,140 | 3,768 | ||||||
|
|
|
|
|||||
Operating income |
18,607 | 18,753 | ||||||
Interest expense, net |
41,415 | 45,739 | ||||||
|
|
|
|
|||||
Income (loss) before income tax provision (benefit) |
(22,808 | ) | (26,986 | ) | ||||
Income tax provision (benefit) |
(9,357 | ) | (9,452 | ) | ||||
|
|
|
|
|||||
Net income (loss) |
$ | (13,451 | ) | $ | (17,534 | ) | ||
|
|
|
|
3
Emdeon Inc.
Condensed Consolidated Balance Sheets
(unaudited and amounts in thousands, except share and per share amounts)
March 31, | December 31, | |||||||
2013 | 2012 | |||||||
ASSETS | ||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 53,321 | $ | 31,763 | ||||
Accounts receivable, net of allowance for doubtful accounts of $4,062 and $3,585 at March 31, 2013 and December 31, 2012, respectively |
206,804 | 190,021 | ||||||
Deferred income tax assets |
3,788 | 4,184 | ||||||
Prepaid expenses and other current assets |
28,985 | 28,160 | ||||||
|
|
|
|
|||||
Total current assets |
292,898 | 254,128 | ||||||
Property and equipment, net |
275,936 | 272,088 | ||||||
Goodwill |
1,481,889 | 1,481,889 | ||||||
Intangible assets, net |
1,702,811 | 1,730,089 | ||||||
Other assets, net |
31,471 | 29,694 | ||||||
|
|
|
|
|||||
Total assets |
$ | 3,785,005 | $ | 3,767,888 | ||||
|
|
|
|
|||||
LIABILITIES AND EQUITY | ||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | 13,518 | $ | 6,223 | ||||
Accrued expenses |
115,916 | 102,069 | ||||||
Deferred revenues |
10,285 | 9,342 | ||||||
Current portion of long-term debt |
23,498 | 17,330 | ||||||
|
|
|
|
|||||
Total current liabilities |
163,217 | 134,964 | ||||||
Long-term debt, excluding current portion |
2,006,198 | 1,999,392 | ||||||
Deferred income tax liabilities |
457,851 | 467,912 | ||||||
Tax receivable agreement obligations to related parties |
129,142 | 125,003 | ||||||
Other long-term liabilities |
7,729 | 8,466 | ||||||
Commitments and contingencies |
||||||||
Equity: |
||||||||
Common stock (par value, $.01), 100 shares authorized and outstanding at March 31, 2013 and December 31, 2012, respectively |
| | ||||||
Additional paid-in capital |
1,132,743 | 1,130,968 | ||||||
Accumulated other comprehensive income (loss) |
(3,396 | ) | (3,789 | ) | ||||
Accumulated deficit |
(108,479 | ) | (95,028 | ) | ||||
|
|
|
|
|||||
Total equity |
1,020,868 | 1,032,151 | ||||||
|
|
|
|
|||||
Total liabilities and equity |
$ | 3,785,005 | $ | 3,767,888 | ||||
|
|
|
|
4
Emdeon Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited and amounts in thousands)
Three Months Ended | Three Months Ended | |||||||
March 31, 2013 | March 31, 2012 | |||||||
Operating activities |
||||||||
Net income (loss) |
$ | (13,451 | ) | $ | (17,534 | ) | ||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
||||||||
Depreciation and amortization |
46,815 | 45,156 | ||||||
Accretion |
4,140 | 3,768 | ||||||
Equity compensation |
1,775 | | ||||||
Deferred income tax expense (benefit) |
(9,917 | ) | (9,956 | ) | ||||
Amortization of debt discount and issuance costs |
2,601 | 2,545 | ||||||
Other |
(34 | ) | 149 | |||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
(16,783 | ) | (188 | ) | ||||
Prepaid expenses and other |
(971 | ) | (6,655 | ) | ||||
Accounts payable |
6,922 | 1,754 | ||||||
Accrued expenses, deferred revenue and other liabilities |
17,817 | 2,802 | ||||||
Tax receivable agreement obligations to related parties |
(103 | ) | (114 | ) | ||||
|
|
|
|
|||||
Net cash provided by (used in) operating activities |
38,811 | 21,727 | ||||||
|
|
|
|
|||||
Investing activities |
||||||||
Purchases of property and equipment |
(13,551 | ) | (15,146 | ) | ||||
|
|
|
|
|||||
Net cash provided by (used in) investing activities |
(13,551 | ) | (15,146 | ) | ||||
|
|
|
|
|||||
Financing activities |
||||||||
Debt principal payments |
(3,252 | ) | (3,060 | ) | ||||
Payments on revolver |
| (15,000 | ) | |||||
Other |
(450 | ) | (68 | ) | ||||
|
|
|
|
|||||
Net cash provided by (used in) financing activities |
(3,702 | ) | (18,128 | ) | ||||
|
|
|
|
|||||
Net increase (decrease) in cash and cash equivalents |
21,558 | (11,547 | ) | |||||
Cash and cash equivalents at beginning of period |
31,763 | 37,925 | ||||||
|
|
|
|
|||||
Cash and cash equivalents at end of period |
$ | 53,321 | $ | 26,378 | ||||
|
|
|
|
5
Explanation of Non-GAAP Financial Measures
Emdeons management believes that, in order to properly understand Emdeons short-term and long-term financial trends, investors may wish to consider the impact of certain non-cash or non-operating items, when used as a supplement to financial performance measures prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). These items result from facts and circumstances that vary in frequency and/or impact continuing operations. In addition, management uses results of operations before such excluded items to evaluate the operational performance of Emdeon as a basis for strategic planning and as a performance evaluation metric in determining achievement of certain executive and management incentive compensation programs. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition to the description provided below, reconciliations of GAAP to non-GAAP results are provided in the financial statement tables included in this release.
In this release, Emdeon defines Adjusted EBITDA as EBITDA (which is defined as net income before income tax provision (benefit), net interest expense and depreciation and amortization), plus certain other non-cash or non-operating items (collectively, EBITDA Adjustments).
To properly evaluate Emdeons business, Emdeon encourages investors to review the GAAP financial information included in this release, and not rely on any single financial measure to evaluate Emdeons business. Emdeon also strongly encourages investors to review the reconciliation of net income (loss) to the non-GAAP measure of Adjusted EBITDA. Adjusted EBITDA, as Emdeon defines it, may differ from and may not be comparable to similarly titled measures used by other companies, because Adjusted EBITDA is not a measure of financial performance under GAAP and is susceptible to varying calculations. Adjusted EBITDA calculations are also used in our credit facilities and indentures, although the adjustments used to calculate Adjusted EBITDA as used in our credit facilities and indentures vary in certain respects among such agreements and from those presented below.
Management uses Adjusted EBITDA to facilitate a comparison of Emdeons operating performance on a consistent basis from period to period that, when viewed in combination with Emdeons GAAP results, management believes provides a more complete understanding of factors and trends affecting Emdeons business than GAAP measures alone. Management believes this non-GAAP measure assists Emdeons board of directors, management, lenders and investors in comparing Emdeons operating performance on a consistent basis because it removes where applicable, the impact of Emdeons capital structure, asset base, acquisition accounting, non-cash charges and non-operating items from Emdeons operations.
6
Emdeon Inc.
Reconciliation of GAAP Net Income to Adjusted EBITDA
(unaudited and amounts in thousands)
Three Months | Three Months | |||||||
Ended March 31, | Ended March 31, | |||||||
2013 | 2012 | |||||||
Net income (loss) |
$ | (13,451 | ) | $ | (17,534 | ) | ||
Interest expense, net |
41,415 | 45,739 | ||||||
Income tax provision (benefit) |
(9,357 | ) | (9,452 | ) | ||||
Depreciation and amortization |
46,815 | 45,156 | ||||||
|
|
|
|
|||||
EBITDA |
65,422 | 63,909 | ||||||
|
|
|
|
|||||
EBITDA Adjustments: |
||||||||
Equity compensation |
1,775 | | ||||||
Acquisition accounting adjustments |
274 | 1,937 | ||||||
Acquisition-related costs |
497 | 927 | ||||||
Transaction-related costs and advisory fees |
1,500 | 2,148 | ||||||
Strategic initiatives, duplicative and transition costs |
2,045 | 5,216 | ||||||
Accretion expense |
4,140 | 3,768 | ||||||
Other |
391 | 538 | ||||||
|
|
|
|
|||||
EBITDA Adjustments |
10,622 | 14,534 | ||||||
|
|
|
|
|||||
Adjusted EBITDA |
$ | 76,044 | $ | 78,443 | ||||
|
|
|
|
7